Acurx Pharmaceuticals (NASDAQ:ACXP) Stock Price Target Cut by HC Wainwright

Acurx Pharmaceuticals (NASDAQ:ACXP) had its target price reduced by stock analysts at HC Wainwright from $31.00 to $11.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has a “buy” rating on the stock.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Acurx Pharmaceuticals has an average rating of “Hold” and a consensus target price of $11.00.

Acurx Pharmaceuticals Stock Down 4.4%

Shares of NASDAQ ACXP traded down $0.04 during trading hours on Thursday, hitting $0.98. The company had a trading volume of 81,633 shares, compared to its average volume of 962,188. The stock has a market capitalization of $5.48 million, a P/E ratio of -0.37 and a beta of -2.08. Acurx Pharmaceuticals has a 1-year low of $0.95 and a 1-year high of $7.54. The firm’s 50 day moving average is $1.23 and its 200-day moving average is $1.92.

Acurx Pharmaceuticals (NASDAQ:ACXP) last issued its earnings results on Thursday, November 12th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11). On average, sell-side analysts predict that Acurx Pharmaceuticals will post -2.00 earnings per share for the current year.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) is a clinical-stage biopharmaceutical company focused on developing novel antibiotics for serious bacterial infections. The company’s research is centered on therapies designed to address pathogens that are resistant to existing treatments. Acurx’s lead product candidate is ibezapolstat, also known as ACX-375, an investigational oral antibiotic being developed for the treatment of Clostridioides difficile infection, commonly known as C. difficile infection.